1- MBBS, M.D. (Medicine) Associate Professor, Department of Medicine. Dr. Panjabrao Deshmukh Medical College, Amravati Maharashtra , INDIA
2- M.D. (Medicine) P.G. Student Department of Medicine, Netaji Shubash Chandra Bosh ,Government Medical College, Jabalpur, Madhya. Pradesh , India
3- MBBS, M.D. (PSM) Associate Professor, Department of Community Medicine. Dr. Panjabrao Deshmukh .Medical College, Amravati Maharashtra ,India
4- PG Student (MD Medicine) Department of Medicine. Dr. Panjabrao Deshmukh .Medical College, Amravati Maharashtra ,India
Abstract: (31261 Views)
Six months administration of bromocriptine mesylate significantly decreased glycated hemoglobin (HbA1c), fasting blood sugar, postprandial blood sugar, and weight of 22 Indian obese patients with type 2 diabetes mellitus with no serious adverse events. Therefore, the novel mechanism of action, efficacy and acceptable safety profile makes this drug an attractive option for treatment of obese type 2 diabetic patients.
Type of Study:
Original Article |
Subject:
Diabetes Received: 2014/03/15 | Accepted: 2014/03/15 | Published: 2014/03/15